Intrinsic host susceptibility among multiple species to intranasal SARS-CoV-2 identifies diverse virological, biodistribution and pathological outcomes.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
04 11 2022
04 11 2022
Historique:
received:
14
07
2022
accepted:
29
10
2022
pubmed:
6
11
2022
medline:
9
11
2022
entrez:
5
11
2022
Statut:
epublish
Résumé
SARS-CoV-2 exhibits a diverse host species range with variable outcomes, enabling differential host susceptibility studies to assess suitability for pre-clinical countermeasure and pathogenesis studies. Baseline virological, molecular and pathological outcomes were determined among multiple species-one Old World non-human primate (NHP) species (cynomolgus macaques), two New World NHP species (red-bellied tamarins; common marmosets) and Syrian hamsters-following single-dose, atraumatic intranasal administration of SARS-CoV-2/Victoria-01. After serial sacrifice 2, 10 and 28-days post-infection (dpi), hamsters and cynomolgus macaques displayed differential virus biodistribution across respiratory, gastrointestinal and cardiovascular systems. Uniquely, New World tamarins, unlike marmosets, exhibited high levels of acute upper airway infection, infectious virus recovery associated with mild lung pathology representing a host previously unrecognized as susceptible to SARS-CoV-2. Across all species, lung pathology was identified post-clearance of virus shedding (antigen/RNA), with an association of virus particles within replication organelles in lung sections analysed by electron microscopy. Disrupted cell ultrastructure and lung architecture, including abnormal morphology of mitochondria 10-28 dpi, represented on-going pathophysiological consequences of SARS-CoV-2 in predominantly asymptomatic hosts. Infection kinetics and host pathology comparators using standardized methodologies enables model selection to bridge differential outcomes within upper and lower respiratory tracts and elucidate longer-term consequences of asymptomatic SARS-CoV-2 infection.
Identifiants
pubmed: 36333445
doi: 10.1038/s41598-022-23339-x
pii: 10.1038/s41598-022-23339-x
pmc: PMC9636276
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
18694Subventions
Organisme : Innovate UK
ID : 971613
Organisme : UK Department of Health and Social Care
Informations de copyright
© 2022. The Author(s).
Références
J Immunol Methods. 2011 May 31;368(1-2):24-35
pubmed: 21334343
Nat Med. 2020 Apr;26(4):450-452
pubmed: 32284615
Emerg Microbes Infect. 2020 Dec;9(1):2673-2684
pubmed: 33251966
Nat Rev Genet. 2021 Dec;22(12):757-773
pubmed: 34535792
Immun Ageing. 2020 Nov 9;17(1):33
pubmed: 33292333
Clin Infect Dis. 2021 Jul 15;73(2):e503-e512
pubmed: 32667973
bioRxiv. 2020 Sep 04;:
pubmed: 32908977
Proc Natl Acad Sci U S A. 2020 Sep 8;117(36):22311-22322
pubmed: 32826334
Signal Transduct Target Ther. 2020 Oct 19;5(1):157
pubmed: 32814760
Sci Total Environ. 2020 Nov 15;743:140444
pubmed: 32649988
Viruses. 2020 Oct 14;12(10):
pubmed: 33066701
Nature. 2022 Jan;601(7891):110-117
pubmed: 34758478
Front Immunol. 2020 Aug 11;11:1991
pubmed: 32903476
NPJ Vaccines. 2021 Jun 17;6(1):83
pubmed: 34140522
Sci Rep. 2019 Oct 10;9(1):14495
pubmed: 31601848
Cell Microbiol. 2010 Jun;12(6):844-61
pubmed: 20088951
Science. 2021 Jan 8;371(6525):172-177
pubmed: 33172935
J Virol. 2021 Mar 10;:
pubmed: 33692203
Emerg Infect Dis. 2020 Sep;26(9):
pubmed: 32568661
Nat Microbiol. 2021 Jan;6(1):73-86
pubmed: 33340034
Clin Infect Dis. 2022 Aug 24;75(1):e1195-e1201
pubmed: 34651164
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Nature. 2020 Oct;586(7830):509-515
pubmed: 32967005
J Virol. 2020 Aug 31;94(18):
pubmed: 32661139
Proc Natl Acad Sci U S A. 2021 Mar 23;118(12):
pubmed: 33658332
Clin Infect Dis. 2020 Dec 3;71(9):2428-2446
pubmed: 32215622
Nat Commun. 2021 Jun 14;12(1):3612
pubmed: 34127676
Lancet Microbe. 2020 Sep;1(5):e218-e225
pubmed: 32838346
Proc Natl Acad Sci U S A. 2021 Feb 23;118(8):
pubmed: 33563754
PLoS Pathog. 2020 Sep 18;16(9):e1008903
pubmed: 32946524
J Gen Virol. 2013 Mar;94(Pt 3):606-611
pubmed: 23152371
Emerg Infect Dis. 2021 Feb;27(2):547-551
pubmed: 33207152
Nature. 2020 Jul;583(7818):834-838
pubmed: 32408338
NPJ Vaccines. 2020 Sep 15;5:86
pubmed: 33014434
PLoS Pathog. 2021 Aug 23;17(8):e1009865
pubmed: 34424943
Sci Transl Med. 2010 Mar 10;2(22):22ra18
pubmed: 20375000
Am J Pathol. 2021 Feb;191(2):274-282
pubmed: 33171111
Emerg Microbes Infect. 2020 Dec;9(1):2322-2332
pubmed: 33028154
Genes (Basel). 2021 Mar 08;12(3):
pubmed: 33800487
Nat Commun. 2021 Feb 24;12(1):1260
pubmed: 33627662
Proc Natl Acad Sci U S A. 2020 Jul 14;117(28):16587-16595
pubmed: 32571934
J Virol. 2020 Oct 27;94(22):
pubmed: 32900822
Emerg Microbes Infect. 2020 Dec;9(1):1824-1834
pubmed: 32726185
Science. 2021 Jan 15;371(6526):288-292
pubmed: 33293339
J Cell Biol. 1973 May;57(2):551-65
pubmed: 4121290
Science. 2020 May 29;368(6494):1012-1015
pubmed: 32303590
Science. 2021 Sep 17;373(6561):eabj0299
pubmed: 34529476
Science. 2020 May 29;368(6494):1016-1020
pubmed: 32269068
Emerg Microbes Infect. 2020 Dec;9(1):2278-2288
pubmed: 33003988
Nat Med. 2020 Nov;26(11):1694-1700
pubmed: 32884153
PLoS Pathog. 2021 May 19;17(5):e1009585
pubmed: 34010360
J Pathol. 2020 Dec;252(4):346-357
pubmed: 32918747
Science. 2020 Aug 14;369(6505):812-817
pubmed: 32434946
PLoS Biol. 2020 Dec 21;18(12):e3001016
pubmed: 33347434
Nat Protoc. 2021 Jun;16(6):3114-3140
pubmed: 33893470
J Virol. 2021 Jan 20;:
pubmed: 33472939
Nature. 2020 Sep;585(7824):268-272
pubmed: 32396922
Cell Rep Med. 2020 Oct 20;1(7):100121
pubmed: 32984855
PLoS Biol. 2020 Jun 8;18(6):e3000715
pubmed: 32511245
J Infect Dis. 2020 Oct 13;222(10):1596-1600
pubmed: 32745172